Browsing: Biologics

WuXi’s stock has fallen 45 percent this year. SING TAO Bloomberg and staff reporter WuXi Biologics…

DUBLIN, Nov. 9, 2023 /PRNewswire/ — The “Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets” report has…

Dublin, Nov. 08, 2023 (GLOBE NEWSWIRE) — The “Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets” report…

SHANGHAI, Sept. 8, 2023 /PRNewswire/ — Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, and WuXi…

Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID…

Solskin The WuXi PharmaTech family of publicly listed companies, emerging as global leaders in outsourced contract services for…

Contract research, development, and manufacturing organisation (CRDMO) WuXi Biologics has announced a proposed spin-off and separate listing of…

Hong Kong – WuXi Biologics (‘WuXi Bio’) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO),…

(Yicai Global) July 10 — Shares of WuXi Biologics rose after the Chinese drug developer said it intends…

Chinese contract research, development and manufacturing organization WuXi Biologics (2269. HK) on Sunday announced the proposed spin-off and…